Publications by authors named "Neil McPhail"
Abiraterone acetate plus prednisolone (AAP) previously demonstrated improved survival in STAMPEDE, a multiarm, multistage platform trial in men starting long-term hormone therapy for prostate cancer. This long-term analysis in metastatic patients was planned for 3 years after the first results. Standard-of-care (SOC) was androgen deprivation therapy.
View Article and Find Full Text PDFPurpose: Docetaxel and abiraterone acetate plus prednisone or prednisolone (AAP) both improve survival when commenced alongside standard of care (SOC) androgen deprivation therapy in locally advanced or metastatic hormone-sensitive prostate cancer. Thus, patient-reported quality of life (QOL) data may guide treatment choices.
Methods: A group of patients within the STAMPEDE trial were contemporaneously enrolled with the possibility of being randomly allocated to receive either docetaxel + SOC or AAP + SOC.
Article Synopsis
- The study investigates the presence and impact of structural variations (SVs) at the BRCA1/2 genes in high-grade serous ovarian carcinoma, emphasizing their contribution to homologous recombination repair deficiency (HRD).
- Using whole-genome and RNA sequencing data from 205 tumors, researchers identified significant occurrences of large deletions in addition to known short somatic mutations (SSMs).
- The findings reveal that SVs, often overlooked, significantly affect patient outcomes and suggest that recognizing these variations can enhance patient selection for HRD-targeted therapies.
Background: Abiraterone acetate plus prednisolone improves survival in men with relapsed prostate cancer. We assessed the effect of this combination in men starting long-term androgen-deprivation therapy (ADT), using a multigroup, multistage trial design.
Methods: We randomly assigned patients in a 1:1 ratio to receive ADT alone or ADT plus abiraterone acetate (1000 mg daily) and prednisolone (5 mg daily) (combination therapy).